Industry News
Pharmaceutical Industry News
FDA bans Lilly, Regeneron antibody use in COVID-19 patients infected by omicron
FDA bans Lilly, Regeneron antibody use in COVID-19 patients infected by omicron kdunleavy Mon, 01/24/2022 - 17:26
Argenx, already deep into its Vyvgart launch, charts course to become immunology ‘powerhouse’: CEO
Argenx, already deep into its Vyvgart launch, charts course to become immunology 'powerhouse': CEO fkansteiner Mon, 01/24/2022 - 14:11
Gilead pulls 2 cancer accelerated approvals as changing lymphoma landscape disrupts confirmatory trial
Gilead pulls 2 cancer accelerated approvals as changing lymphoma landscape disrupts confirmatory trial aliu Mon, 01/24/2022 - 11:34
On second thought, Oncopeptides decides not to give up on Pepaxto in the U.S., but won’t say why
On second thought, Oncopeptides decides not to give up on Pepaxto in the U.S., but won't say why kdunleavy Mon, 01/24/2022 - 11:28
Pfizer takes a surprising hit to its rare disease plan as FDA snubs new growth deficiency med
Pfizer takes a surprising hit to its rare disease plan as FDA snubs new growth deficiency med aliu Mon, 01/24/2022 - 10:27
With omicron on the prowl, FDA extends inspection pause into February
With omicron on the prowl, FDA extends inspection pause into February fkansteiner Mon, 01/24/2022 - 10:01
AbbVie’s Skyrizi nabs psoriatic arthritis nod, its second, shortly after Rinvoq
AbbVie's Skyrizi nabs psoriatic arthritis nod, its second, shortly after Rinvoq fkansteiner Mon, 01/24/2022 - 09:03
AbbVie’s Skyrizi nabs psoriatic arthritis nod, its 2nd, shortly after Rinvoq
AbbVie's Skyrizi nabs psoriatic arthritis nod, its 2nd, shortly after Rinvoq fkansteiner Mon, 01/24/2022 - 09:03
AstraZeneca taps E! host Nina Parker for asthma campaign as it hopes new drug Tezspire can ‘break the cycle’
AstraZeneca taps E! host Nina Parker for asthma campaign as it hopes new drug Tezspire can 'break the cycle’ badams Mon, 01/24/2022 - 08:59
Gilead’s Veklury expands FDA nod to patients outside the hospital as oral version heads to trial
Gilead's Veklury expands FDA nod to patients outside the hospital as oral version heads to trial aliu Mon, 01/24/2022 - 06:57
BDSI readies liquid migraine medicine launch but stays away from ‘broad blast’ marketing campaign
BDSI readies liquid migraine medicine launch but stays away from 'broad blast' marketing campaign sharon.coey Mon, 01/24/2022 - 04:29
Less selling, more science can best help doctors navigate complex new cancer treatments, report suggests
Less selling, more science can best help doctors navigate complex new cancer treatments, report suggests nmissakian Sun, 01/23/2022 - 13:51
F.D.A. Approves Remdesivir for Patients Not Hospitalized
The treatment must be given via intravenous infusion over three consecutive days, generally at a hospital or clinic.
Poland’s largest pharma scouts for joint bidder in potential $4B buyout of former Sanofi generics unit: Reuters
Poland’s largest pharma scouts for joint bidder in potential $4B buyout of former Sanofi generics unit: Reuters aliu Fri, 01/21/2022 - 11:30
Fierce JPM Week: Bristol Myers’ next-gen autoimmune med not just another JAK drug, exec says
Fierce JPM Week: Bristol Myers' next-gen autoimmune med not just another JAK drug, exec says esagonowsky Fri, 01/21/2022 - 11:04
It’s a matter of national security: Sanofi doesn’t want new high-rise neighbors watching its Toronto plant
It's a matter of national security: Sanofi doesn't want new high-rise neighbors watching its Toronto plant kdunleavy Fri, 01/21/2022 - 10:25
GlaxoSmithKline rushes to accelerate COVID-19 antibody output amid omicron-driven demand
GlaxoSmithKline rushes to accelerate COVID-19 antibody output amid omicron-driven demand aliu Fri, 01/21/2022 - 09:50
The Chief of CVS Health Wants to Be Part of People’s ‘Everyday Life’
Karen S. Lynch, who took over during the pandemic, is dealing with insurance, opioids, vaccines, politics and more.
You say Trintellix, I say Brintellix: Why a drug name in the US won’t always translate across the pond
You say Trintellix, I say Brintellix: Why a drug name in the US won't always translate across the pond badams Fri, 01/21/2022 - 07:07
Fierce Pharma Asia—Lilly-Abbisko cardiometabolic pact; Daiichi Sankyo asset sale; Eisai’s next Alzheimer’s prospect
Fierce Pharma Asia—Lilly-Abbisko cardiometabolic pact; Daiichi Sankyo asset sale; Eisai's next Alzheimer's prospect aliu Fri, 01/21/2022 - 06:45